ESMO 2023: Efficacy of immune checkpoint inhibition in metastatic or nonresectable melanoma after failure of adjuvant anti PD1 treatment - A EUMelaReg real world evidence study
Authors: M. Weichenthal, D. Schadendorf, L. Bastholt et al.
ASCO 2022: EMRseq: Registry based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF/MEK inhibition
Authors: L. Bastholt, I.M. Svane, D. Schadendorf et al.
EADO 2022: Combi-EU: BRAF-/MEK-Inhibition with Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: Interim Analysis of an Observational Study on a Treatment supporting Electronic Health App.
Authors: M. Weichenthal, P. Mohr, E. Livingstone et al.